Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japan Gaucher Research-002 observational ERT bone study
jRCT1090220305Recruiting
- Sponsor
- Kazuya Tsuboi
- Start
- Jul 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of imiglucerase and velaglucerase alfa in Gaucher disease (GD) (2 arms), sponsored by Kazuya Tsuboi. Primary endpoint: Evaluation of bone lesions and long-term efficacy of enzyme replacement therapy. Started Jul 2017; status: recruiting.
02
Drugs
imiglucerasevelaglucerase alfa
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on jRCT1090220305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220305.